PSA testing
This article was originally published in The Gray Sheet
Executive Summary
Prostate biopsies should be triggered by a lower threshold of prostate-specific antigen than currently is the norm, according to a 6,691-patient study in the July 24 issue of The New England Journal of Medicine. Traditionally, biopsies are ordered for patents with a PSA level of 4.1 ng per milliliter or greater, but 82% of cancers in men under 60, as well as 65% of cancers in older men, are missed using that threshold, according to the study authors Rinaa Punglia, MD, Harvard Medical School, et al...